Month: May 2020

GUANGZHOU, China, May 12, 2020 (GLOBE NEWSWIRE) — EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company, today announced that it has been invited to participate in the 5th Annual Oppenheimer Emerging Growth Virtual Conference on Tuesday, May 12, 2020.The conference will feature virtual one-on-one meetings with emerging growth companies in technology, industrial growth and consumer sectors. Richard Liu, Chief Financial Officer of EHang will host one-on-one meetings to discuss the Company’s latest business development via teleconference throughout the day.Institutional investors interested in scheduling a one-on-one conference meeting with EHang are encouraged to contact your Oppenheimer sales representative or EHang’s Investor...

WATERLOO, Ontario, May 12, 2020 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq: DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that freight forwarders, such as California’s Aqualine International and Puerto Rico’s E.T.H. Cargo Services, are improving their responsiveness to interruptions in the transport of ocean cargo due to COVID-19 by using Descartes’ cloud-based solutions to streamline back office operations, regulatory compliance, security filings, and global trade flow analysis.  “We provide freight forwarding services that cover all of the major ports in the world and have always done so as an office-based business,” said Makiko Yamamoto, Managing Director at Aqualine International. “Thanks to Descartes’ cloud-based forwarding solution with role-based access and document...

Alpha-1 Antitrypsin Deficiency Program Demonstrates More than Four-Fold Increase in Circulating Levels of Functional Protein Following Durable Direct Correction In VivoNovel HbG-Makassar Program for Sickle Cell Disease Demonstrates Direct Correction Levels Greater than 80% with Corresponding HbS Globin Reduction to Less than 20% Base Editing Program to Recreate Hereditary Persistence of Fetal Hemoglobin Shows Greater than 90% Editing and 65% Increase in Gamma Globin Protein after 16 weeks EngraftmentCAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported additional data from multiple oral and poster presentations during the ongoing 23rd American Society of Gene and Cell Therapy (ASGCT) Annual Meeting...

Phase I/IIa clinical study of BriaCell’s lead candidate, Bria-IMT™, for breast cancer treatment, with Incyte Corporation’s immune checkpoint inhibitor, INCMGA00012, is ongoing and recruiting patients amidst the COVID-19 pandemic.BriaCell is currently evaluating a number of business strategies to develop its potential treatments for breast cancer on its own or in partnership.Clinical and pathological findings of Bria-IMT™, alone or in combination with checkpoint inhibitors, KEYTRUDA® and INCMGA00012, in advanced breast cancer will be presented at upcoming conferences.BERKELEY, Calif. and VANCOUVER, British Columbia, May 12, 2020 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer,...

TORONTO, Ontario and CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique, core technology to predict novel targets on the molecular surface of complex proteins, has advanced its program to develop a high-throughput, highly accurate test for detection of antibodies to SARS CoV-2, the causative agent of COVID-19.  ProMIS has identified 18 potential antibody targets unique to the spike protein halo of SARS CoV-2. These targets, called conformational peptide antigens, will be synthesized by a specialized contract laboratory organization over the coming weeks for subsequent testing and validation in the serology lab of Dr. Hans Frykman at the University of British Columbia. This antibody test could become commercially available in the near term.As states, provinces...

Paris, le 11 mai 2020COMPTE-RENDU DEL’ASSEMBLEE GENERALE MIXTE DU 11 MAI 2020APPROBATION DES COMPTES 2019Dans le contexte de l’épidémie du Covid-19, et conformément à l’article 4 de l’ordonnance 2020-321 du 25 mars 2020, l’Assemblée générale mixte des actionnaires de HighCo, qui s’est tenue à huis clos lundi 11 mai 2020, a approuvé les comptes sociaux et consolidés de l’exercice clos le 31 décembre 2019 ainsi que l’affectation en réserve du bénéfice de cet exercice.AUTRES RÉSOLUTIONSL’Assemblée générale mixte a adopté toutes les autres résolutions proposées et notamment le renouvellement pour six exercices du mandat de commissaire aux comptes titulaire du Cabinet Jean Avier.A propos de HighCoExpert en data marketing et communication, HighCo innove en permanence pour relever avec les marques et retailers les challenges du commerce de demain.Cotée...

Intellia’s CRISPR/Cas9 proprietary process produces multiple, highly efficient sequential edits in T cells that have superior function and minimal translocations, compared to results from standard T cell engineering approachesProprietary process supports NTLA-5001 and other potential therapies for solid tumors In our hereditary angioedema program, demonstrated durability in reduction of therapeutically relevant marker in non-human primate study for our newest development candidate, NTLA-2002CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, is presenting three oral presentations and two poster presentations at the 23rd Annual Meeting of the American Society...

CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today presented preclinical data supporting its lead artificial antigen-presenting cell (aAPC) program, RTX-321, for the potential treatment of HPV 16-positive tumors at the American Society of Gene and Cell Therapy 23rd Annual Meeting. The meeting is being held virtually from May 12 – 15, 2020.“Today, we presented preclinical in vitro data supporting the development of RTX-321 for the treatment of HPV 16-positive tumors by demonstrating that we can expand the different cell populations – effector and long-lived memory CD8+ cells – that are critical for delivering and maintaining long-term,...

London, May 12, 2020STEYR, the premium short-liner agricultural brand of CNH Industrial N.V. (NYSE:CNHI / MI:CNHI), has received the prestigious Platinum Award in the 2020 MUSE Design Awards Competition in the Concept Design category. Conferred by a jury composed of renowned international design professionals and leading industry specialists, the STEYR Konzept succeeded in a field of some 3,000 entrants. The MUSE Creative and MUSE Design Awards, established by the International Awards Associate Inc., recognize the achievements of design professionals from around the world hailing from a range of disciplines.Combining innovative technologies in a unique, sustainable and potentially zero emission package, STEYR, in partnership with sister powertrain brand FPT Industrial, created the STEYR Konzept, which encapsulates a future vision for...

ROUYN-NORANDA, Quebec, May 12, 2020 (GLOBE NEWSWIRE) — Radisson Mining Resources Inc. (TSX-V: RDS, OTC: RMRDF): (“Radisson” or the “Company”) announces today that in line with the Governement of Quebec announcement on May 7, 2020, it is resuming exploration activities at the O’Brien gold project. The 100% owned O’Brien gold project is located along the Larder-Lake-Cadillac Break, halfway between Rouyn-Noranda and Val-d’Or in Abitibi-Témiscamingue, Quebec. Pursuant to the Government of Quebec directives, the head-office remains closed and teleworking remains in place for all departments else than for exploration activities at the O’Brien gold project.To date, Radisson has had no suspected or confirmed cases of COVID-19 and had implemented a specific COVID-19 protocol on March 12 to protect its employees. The health and safety...